CDK Stock Recent News

CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader, MRT-51443, to treat HR-positive/HER2-negative breast cancer at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, IL. “In preclinical models of HR-positive/HER2-negative breast cancer, the combination of MRT-51443 with a CDK4/6 inhibito

Company is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. The company is also progressing REC-994 for Cerebral Cavernous Malformation, with phase 2 data expected to be published and FDA guidance sought for further development. The global solid tumor market is expected to reach $375.4 billion by 2034.

AUSTIN, Texas--(BUSINESS WIRE)-- #CDKGlobal--CDK, the leading automotive retail software provider, today announced the extension of its agreement with Sonic Automotive, Inc. (NYSE: SAH), one of the nation's largest automotive and powersports retailers, to provide its dealerships with the CDK Dealer Management System (DMS) and its Dealership Xperience Modern Retail Suite, a set of powerful software tools that connects the consumer-to-dealer buying journey into a single, unified transaction for a more satisfy.

CDK cyberattack results in operational chaos in the auto retail industry, forcing dealerships into manual mode and sparking industry-wide cybersecurity reassessments.

Group 1 Automotive Inc. GPI, -0.36% said Monday the cyber-attack at software provider CDK Global last week has disrupted its business applications and processes at U.S. operations that rely on CDK's dealers' systems. “In response, the company immediately activated its cyber incident response procedures and proactively took measures to protect and isolate its systems from CDK's platform,” Houston-based Group 1 said in a statement.

HOUSTON , June 24, 2024 /PRNewswire/ -- Group 1 Automotive, Inc. (NYSE: GPI) ("Group 1" or the "Company"), a Fortune 300 automotive retailer with 202 dealerships located in the U.S. and U.K., today announced that the cybersecurity incident recently experienced by third-party software provider, CDK Global LLC ("CDK"), has disrupted Group 1's business applications and processes in its U.S. operations that rely on CDK's dealers' systems.  In response, the Company immediately activated its cyber incident response procedures and proactively took measures to protect and isolate its systems from CDK's platform.

The firm says on its website that its software is used by nearly 15,000 car dealers

AUSTIN, Texas--(BUSINESS WIRE)--Top Publicly Held Dealer Group 1 Automotive Goes All-In on Innovation with CDK Dealership Xperience Platform.

-- Updated Phase 1 dose escalation data show that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting toxicities -- -- Early signal of clinical activity includes compelling biomarker reductions correlated with BLU-222 exposure -- CAMBRIDGE, Mass. , May 23, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced updated data from the ongoing Phase 1 dose escalation portion of the VELA clinical trial of BLU-222, an investigational, highly selective and potent CDK2 inhibitor, in combination with ribociclib and fulvestrant in patients with hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer.

Here is how CDK Global (CDK) and Gree (GREZF) have performed compared to their sector so far this year.